BACKGROUND:Abnormal expression of the cell cycle regulatory proteins p27(Kip1) (p27) and cyclin E may be associated with breast cancer survival and relapse. We studied these markers in a clinical trial setting with patients with breast cancer treated by a uniform drug regimen so that treatment was not associated with variability in outcome. METHODS: We used tissue microarrays to evaluate the expression of p27 and cyclin E proteins by immunohistochemistry in tumor tissue from 2123 (68%) of 3122 patients with moderate-risk primary breast cancer who were enrolled in Southwest Oncology Group-Intergroup Trial S9313, in which patients were assigned to receive doxorubicin and cyclophosphamide administered concurrently (n = 1595) or sequentially (n = 1527). Disease-free and overall survival were equivalent in the two arms. Expression of the proteins was rated on a scale of 1-7, and the median value was used as the cut point. Log-rank tests and Cox regression analyses were used to assess associations with survival. Overall survival was defined as time to death from all causes; disease-free survival was defined as time to recurrence or death. All P values were from two-sided statistical tests. RESULTS: Lower p27 expression was associated with worse overall survival (unadjusted hazard ratio [HR] = 1.50, 95% confidence interval [CI] = 1.21 to 1.86) and disease-free survival (unadjusted HR = 1.31, 95% CI = 1.10 to 1.57) than higher p27 expression. Among hormone receptor-positive patients, lower p27 expression was associated with worse overall survival (HR = 1.42, 95% CI = 1.05 to 1.94) and worse disease-free survival (HR = 1.27, 95% CI = 0.99 to 1.63) than higher p27 expression after adjustment for treatment, menopausal status, tumor size, and number of positive lymph nodes. Among these patients, 5-year overall survival associated with higher p27 expression (0.91, 95% CI = 0.89 to 0.93) was similar to that associated with lower p27 expression (0.85, 95% CI = 0.82 to 0.87). No association between p27 expression and survival was found in hormone receptor-negative patients. Cyclin E expression was not statistically significantly associated with overall survival (HR = 1.12, 95% CI = 0.91 to 1.38) or disease-free survival (HR = 1.09, 95% CI = 0.92 to 1.29). CONCLUSIONS: Low p27 expression appears to be associated with poor prognosis, especially among patients with steroid receptor-positive tumors.
RCT Entities:
BACKGROUND: Abnormal expression of the cell cycle regulatory proteins p27(Kip1) (p27) and cyclin E may be associated with breast cancer survival and relapse. We studied these markers in a clinical trial setting with patients with breast cancer treated by a uniform drug regimen so that treatment was not associated with variability in outcome. METHODS: We used tissue microarrays to evaluate the expression of p27 and cyclin E proteins by immunohistochemistry in tumor tissue from 2123 (68%) of 3122 patients with moderate-risk primary breast cancer who were enrolled in Southwest Oncology Group-Intergroup Trial S9313, in which patients were assigned to receive doxorubicin and cyclophosphamide administered concurrently (n = 1595) or sequentially (n = 1527). Disease-free and overall survival were equivalent in the two arms. Expression of the proteins was rated on a scale of 1-7, and the median value was used as the cut point. Log-rank tests and Cox regression analyses were used to assess associations with survival. Overall survival was defined as time to death from all causes; disease-free survival was defined as time to recurrence or death. All P values were from two-sided statistical tests. RESULTS: Lower p27 expression was associated with worse overall survival (unadjusted hazard ratio [HR] = 1.50, 95% confidence interval [CI] = 1.21 to 1.86) and disease-free survival (unadjusted HR = 1.31, 95% CI = 1.10 to 1.57) than higher p27 expression. Among hormone receptor-positive patients, lower p27 expression was associated with worse overall survival (HR = 1.42, 95% CI = 1.05 to 1.94) and worse disease-free survival (HR = 1.27, 95% CI = 0.99 to 1.63) than higher p27 expression after adjustment for treatment, menopausal status, tumor size, and number of positive lymph nodes. Among these patients, 5-year overall survival associated with higher p27 expression (0.91, 95% CI = 0.89 to 0.93) was similar to that associated with lower p27 expression (0.85, 95% CI = 0.82 to 0.87). No association between p27 expression and survival was found in hormone receptor-negative patients. Cyclin E expression was not statistically significantly associated with overall survival (HR = 1.12, 95% CI = 0.91 to 1.38) or disease-free survival (HR = 1.09, 95% CI = 0.92 to 1.29). CONCLUSIONS: Low p27 expression appears to be associated with poor prognosis, especially among patients with steroid receptor-positive tumors.
Authors: P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts Journal: Nat Med Date: 1997-02 Impact factor: 53.440
Authors: J Nourse; E Firpo; W M Flanagan; S Coats; K Polyak; M H Lee; J Massague; G R Crabtree; J M Roberts Journal: Nature Date: 1994-12-08 Impact factor: 49.962
Authors: M V Ponce-Castañeda; M H Lee; E Latres; K Polyak; L Lacombe; K Montgomery; S Mathew; K Krauter; J Sheinfeld; J Massague Journal: Cancer Res Date: 1995-03-15 Impact factor: 12.701
Authors: J A Pietenpol; S K Bohlander; Y Sato; N Papadopoulos; B Liu; C Friedman; B J Trask; J M Roberts; K W Kinzler; J D Rowley Journal: Cancer Res Date: 1995-03-15 Impact factor: 12.701
Authors: M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe Journal: Science Date: 1995-08-04 Impact factor: 47.728
Authors: David L Rimm; Torsten O Nielsen; Scott D Jewell; Daniel C Rohrer; Gloria Broadwater; Frederic Waldman; Kisha A Mitchell; Baljit Singh; Gregory J Tsongalis; Wendy L Frankel; Anthony M Magliocco; Jonathan F Lara; Eric D Hsi; Ira J Bleiweiss; Sunil S Badve; Beiyun Chen; Peter M Ravdin; Richard L Schilsky; Ann Thor; Donald A Berry Journal: J Clin Oncol Date: 2011-04-25 Impact factor: 44.544
Authors: Amy R Peck; Agnieszka K Witkiewicz; Chengbao Liu; Ginger A Stringer; Alexander C Klimowicz; Edward Pequignot; Boris Freydin; Thai H Tran; Ning Yang; Anne L Rosenberg; Jeffrey A Hooke; Albert J Kovatich; Marja T Nevalainen; Craig D Shriver; Terry Hyslop; Guido Sauter; David L Rimm; Anthony M Magliocco; Hallgeir Rui Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: Kelly K Hunt; Khandan Keyomarsi; Cansu Karakas; Min Jin Ha; Anna Biernacka; Min Yi; Aysegul A Sahin; Opoku Adjapong; Gabriel N Hortobagyi; Melissa Bondy; Patricia Thompson; Kwok Leung Cheung; Ian O Ellis; Sarah Bacus; W Fraser Symmans; Kim-Anh Do Journal: Clin Cancer Res Date: 2016-11-23 Impact factor: 12.531
Authors: Raymond Tubbs; William E Barlow; G Thomas Budd; Eric Swain; Peggy Porter; Allen Gown; I-Ten Yeh; George Sledge; Charles Shapiro; James Ingle; Charles Haskell; Kathy S Albain; Robert Livingston; Daniel F Hayes Journal: J Clin Oncol Date: 2009-07-20 Impact factor: 44.544
Authors: Cynthia E Glover; Kay E Gurley; Kyung-Hoon Kim; Barry Storer; Mathew L Fero; Christopher J Kemp Journal: Carcinogenesis Date: 2009-04-20 Impact factor: 4.944
Authors: Cansu Karakas; Anna Biernacka; Tuyen Bui; Aysegul A Sahin; Min Yi; Said Akli; Jolie Schafer; Angela Alexander; Opoku Adjapong; Kelly K Hunt; Khandan Keyomarsi Journal: Am J Pathol Date: 2016-05-13 Impact factor: 4.307